U.S. Infrastructure Stock News

NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (VKTX) Stock Still Looks Pricey With Pipeline Hopes Priced In

Viking Therapeutics has delivered a very large 463.7% return over the past five years, yet the stock currently screens as expensive on the valuation checks, which raises questions about how much optimism is already in the price. Over five years, Viking Therapeutics has returned 463.7%, which signals investors have already paid up heavily for the growth story. Expectations for future revenue and cash flow from Viking Therapeutics' pipeline can support a premium, although any delay in turning...
NYSE:WWW
NYSE:WWWLuxury

Why Wolverine World Wide (WWW) Is Up 9.8% After Raising 2026 Guidance And What It Means

In August 2026, Wolverine World Wide raised its full-year 2026 guidance, now expecting US$1.98–US$2.00 billion in revenue, higher operating margins of about 9.5%, and diluted EPS of US$1.48–US$1.58 after reporting second-quarter sales of US$506.4 million and net income of US$31.2 million, both above the prior year. This guidance increase, alongside year-over-year growth in both quarterly and year-to-date earnings, suggests Wolverine’s recent operational initiatives are feeding through to...
NYSE:SSB
NYSE:SSBBanks

SouthState’s New Government Contractor Banking Push Might Change The Case For Investing In SSB

SouthState Bank recently expanded into Government Contractor Banking, appointing veteran banker and former MartinFederal Consulting CEO David Mathis to lead the new vertical and support clients with financing, treasury management, capital markets, and mergers and acquisitions services. This move introduces a specialized focus on the government contracting sector, pairing niche industry knowledge with commercial banking capabilities to broaden SouthState’s business banking offering. We’ll now...
NYSE:NWN
NYSE:NWNGas Utilities

Northwest Natural Holding (NWN) Guides To Upper Half Of EPS Range, Is It Still 11% Undervalued?

Northwest Natural Holding (NWN) stock is in focus after the company reported second quarter 2026 results, swung to a small net profit, and guided full year earnings per share toward the upper half of its 2026 range. See our latest analysis for Northwest Natural Holding. Northwest Natural Holding shares have edged higher in recent months, with a 90 day share price return of 2.2% and a year to date share price return of 9.16%. The 1 year total shareholder return of 30.75% and 3 year total...
NasdaqGS:DDOG
NasdaqGS:DDOGSoftware

Is Datadog (DDOG) Fairly Valued Following Its FedRAMP High Win And Vertosoft Partnership?

Datadog (DDOG) is drawing fresh attention after securing FedRAMP High certification for Datadog for Government and partnering with Vertosoft, a move that points directly to the US public sector opportunity. See our latest analysis for Datadog. Set against these government wins, Datadog’s share price has had a mixed few weeks, with a 30 day share price return down 4.9%, a 90 day share price return of 15.9%, and a 1 year total shareholder return of 90.7%. This points to momentum that has built...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Relay Therapeutics (RLAY) Stock May Be Fully Valued After A 7x Run

Relay Therapeutics has delivered a very large 1 year return, yet the stock currently screens as expensive on broad valuation checks, which raises questions about how much optimism is already in the price. Relay Therapeutics has returned roughly 7x over the past 12 months, which puts unusual weight on whether the fundamentals can justify that kind of move. Expectations for future drug development and potential revenue can support the current valuation, while uncertainty around clinical...
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

PTC Therapeutics recently held a special call to discuss the past regulatory progress of ST-920, whose Biologics License Application is supported by 52-week Phase 1/2 STAAR data showing meaningful renal benefit alongside a favorable safety and tolerability profile. This focus on ST-920’s clinical and regulatory trajectory highlights PTC’s deepening commitment to rare disease gene therapies and potential portfolio diversification beyond its current commercial base. We’ll now examine how...
NYSE:CW
NYSE:CWAerospace & Defense

Curtiss Wright (CW) Expands Buyback Program, Is The Stock Still Below Fair Value?

Curtiss-Wright (CW) extended its share repurchase activity on August 10, 2026, adding US$100 million to its buyback authorization and bringing the total program size to US$2.166 billion. See our latest analysis for Curtiss-Wright. Curtiss-Wright’s latest buyback expansion comes after a brief period of share price softness, with the stock down over the past quarter but still showing strong year to date share price returns and very strong multi year total shareholder returns. If this kind of...
NYSE:KMI
NYSE:KMIOil and Gas

Kinder Morgan (KMI) Stock Looks Like A Bargain On Cash Flow, Fair On Earnings

Kinder Morgan stock has delivered strong returns over the past few years, yet the current price near US$32.87 is still below an intrinsic value estimate from a Discounted Cash Flow (DCF) approach that points to roughly 40.4% upside. At the same time, market multiples suggest Kinder Morgan is trading at about the right level overall, which creates a mixed read on how much value is really left in the share price today. Over the past 5 years Kinder Morgan has returned about 161.3%, which puts...
NYSE:XYZ
NYSE:XYZDiversified Financial

Block (SQ) Stock Still Looks Undervalued Despite Its 71% Five Year Fall

Block stock is caught between two different valuation signals. The Excess Returns intrinsic value estimate points to meaningful upside from the current US$79.43 share price, while earnings based multiples flag the stock as expensive compared with its fundamentals. Block has declined 70.6% over the past 5 years, which leaves long term holders with a weak result and makes today’s entry point more sensitive to valuation. Recent AI driven restructuring and product rollout can support margin and...
NYSE:COTY
NYSE:COTYPersonal Products

Is Coty (COTY) Undervalued Going Into Earnings?

Earnings expectations put Coty in focus Coty (COTY) is back in the spotlight as investors look ahead to fiscal fourth quarter earnings, with multiple firms expecting results to align with the company’s conservative sales guidance and to present limited surprises compared with prior commentary. See our latest analysis for Coty. Recent trading reflects this mixed setup for Coty, with the share price up 40.51% over 90 days and 4.98% over 30 days, yet the 1 year total shareholder return declined...
NYSE:BRK.A
NYSE:BRK.ADiversified Financial

Will Berkshire’s Big Alphabet Bet and Renewed Stock Buying Change Berkshire Hathaway's (BRK.A) Narrative

In early August 2026, Berkshire Hathaway reported Q2 results showing revenue of US$101.81 billion and net income of US$25.67 billion, both higher than a year earlier, while also ramping up equity purchases and buybacks under new CEO Greg Abel. A key shift was Berkshire’s very large expansion of its Alphabet stake via a US$10 billion private placement and market purchases, ending a 14‑quarter stretch of net stock selling and signaling a different capital deployment approach. We’ll now examine...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Harrow (HROW) Reaffirms 2026 Guidance, Is The Upside Already Priced In?

Event recap and why Harrow stock is in focus Harrow (HROW) is back on investor radar after the company reiterated its 2026 revenue guidance of US$350 million to US$365 million and reported second quarter results that paired higher sales with a wider net loss. The stock has risen over the past 3 months but is down over the past month. That backdrop makes the latest guidance and earnings release an important checkpoint for anyone tracking Harrow’s eyecare focused plans. See our latest analysis...
NYSE:STE
NYSE:STEMedical Equipment

Should STERIS’ (STE) Record Chemistries Investment and Reaffirmed Outlook Require Action From Investors?

In early August 2026, STERIS plc reported first-quarter fiscal 2027 results showing higher sales of US$1,492.7 million and increased earnings, reiterated its full-year revenue growth guidance of 7% to 8%, appointed Pierre Boulud to key board committees, and announced a US$600 million chemistries Center of Excellence in North Carolina. The combination of earnings growth, reaffirmed guidance, and the largest manufacturing investment in the company’s history highlights management’s confidence...
NasdaqGM:HVII
NasdaqGM:HVIICapital Markets

Harrow And 2 Other Growth Stocks Insiders Are Betting On

In the last week, the United States market has remained flat, although it is up 20% over the past year with earnings forecasted to grow by 17% annually. In such a promising environment, growth companies with high insider ownership can be particularly appealing as insiders' confidence in their own firms often signals potential for sustained expansion and value creation.
NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

Identiv Leads The Charge In These 3 Promising Penny Stocks

Over the last 7 days, the United States market has remained flat, although it is up 20% over the past year, with earnings expected to grow by 17% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to represent real potential for investors seeking affordability and growth when backed by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and potential for...
NYSE:BF.B
NYSE:BF.BBeverage

Brown Forman (BF.B) Stock Looks Undervalued On Cash Flow Yet Fair On Earnings

Brown-Forman stock has delivered a steep decline of about 56.6% over the past five years, yet its current checks suggest a more nuanced valuation picture where the Discounted Cash Flow (DCF) estimate points to meaningful upside while market multiples look closer to fair value. Over five years, Brown-Forman’s share price has fallen about 56.6%, which raises questions about whether expectations have reset too far compared to the company’s fundamentals. Future cash flow and margin expectations...
NasdaqGS:MRVL
NasdaqGS:MRVLSemiconductor

Marvell (MRVL) Stock Looks Strong On Cash Flow But Rich On Earnings

After a three year run that has lifted Marvell Technology shares well over 200%, the stock now screens as expensive, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples pointing to a premium price tag. Recent swings around AI optimism, higher Treasury yields and upcoming earnings have only sharpened the question of how much future growth is already built into Marvell's valuation. Marvell Technology has returned 254.5% over the past three years, which means...
NYSE:MTZ
NYSE:MTZConstruction

MasTec (MTZ) Completes $647.8 Million Notes Offering On A Valuation That Still Looks Cheap

MasTec (MTZ) has drawn fresh investor attention after completing a US$647.764 million fixed income offering in 5.850% senior notes due 2036, a move that could influence its funding mix and project pipeline. See our latest analysis for MasTec. MasTec’s share price has been volatile around this funding move, with the stock down 7.39% on a 1-day share price return and 27.09% over 90 days, yet still showing a 23.05% year to date share price gain and a 59.84% 1-year total shareholder return. This...
NYSE:VZ
NYSE:VZTelecom

Verizon (VZ) Loses Supreme Court Bid To Recover FCC Privacy Fine

Verizon Communications (NYSE: VZ) has had its petition rejected by the U.S. Supreme Court, leaving in place a multimillion dollar FCC fine tied to sales of customers' real time location data. The decision ends Verizon's legal challenge and confirms the financial penalty imposed over its handling of sensitive user information. The outcome renews focus on Verizon's regulatory exposure and the privacy rules that apply to major U.S. telecom carriers. With regulators tightening their focus on...
NYSE:CVX
NYSE:CVXOil and Gas

Should Chevron’s (CVX) Angola Tie-Back Discovery Reshape How Investors View Its Infrastructure Strategy?

Chevron recently confirmed an oil and gas condensate discovery at the 105-4X exploration well in Angola’s offshore Block 0, which it is evaluating for development as a tie-back to nearby existing facilities to potentially accelerate development timelines and lower unit costs. This Angola find highlights Chevron’s focus on infrastructure-led exploration in Sub-Saharan Africa, adding to its resource base while aiming to use existing platforms and pipelines more efficiently. We’ll now examine...
NYSE:TAL
NYSE:TALConsumer Services

What Is Driving TAL Education Group (TAL) Higher Today?

Market discussion around TAL Education Group (NYSE:TAL) has picked up after commentators highlighted its lower PEG ratio and P/B ratio compared with peers. This has prompted investors to reassess the stock’s current pricing and earnings outlook. See our latest analysis for TAL Education Group. TAL Education Group's recent trading reflects this renewed interest, with a 1-month share price return of 17.48% and a 3-month share price return of 14.90% indicating building momentum. The 3-year total...
NYSE:CBL
NYSE:CBLRetail REITs

CBL & Associates Properties (CBL) Faces A Fair Value Gap As 2026 Guidance Improves

CBL & Associates Properties (CBL) is back in focus after its August earnings update, which showed higher quarterly and half year sales and net income, along with new full year 2026 earnings guidance. See our latest analysis for CBL & Associates Properties. At a share price of US$56.66, CBL & Associates Properties has cooled slightly in the very short term, yet a 30 day share price return of 2.51% and 90 day share price return of 18.73% sit alongside a year to date share price return of 53.43%...